Ipsen ((GB:0MH6)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Ipsen is conducting a clinical study titled ‘An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours.’ The study aims to determine the appropriate dosage, safety, and effectiveness of IPN01194 in adults with advanced solid tumours, which are cancers that have spread from their original site.
Intervention/Treatment: The study tests the drug IPN01194, an ERK1/2 inhibitor, administered orally to participants. The drug is intended to assess its safety and antitumour activity in treating advanced solid tumours.
Study Design: This interventional study is divided into two phases: Phase I involves dose escalation with backfilling, while Phase IIa is a cohort expansion. The study is randomized, sequential, and open-label, with no masking, focusing on treatment as its primary purpose.
Study Timeline: The study began on February 27, 2024, with the latest update on August 27, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.
Market Implications: The progress of this study could significantly impact Ipsen’s stock performance and investor sentiment, as successful results may enhance the company’s portfolio in oncology. Competitors in the oncology drug market will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.